Spots Global Cancer Trial Database for A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer

Official Title: A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer

Study ID: NCT00498407

Conditions

Advanced Colorectal Cancer

Colorectal Cancer

Interventions

CP-4055

Study Description

Brief Summary: Patients with histologically or cytologically confirmed metastatic colorectal cancer (CRC) who have failed a first-line chemotherapeutic regimen containing oxaliplatin and 5-fluorouracil (5-FU) with or without bevacizumab, with or without other Investigational Medicinal Products (IMPs), will receive CP-4055 200 mg/m2/day intravenously (IV) on Day 1-5 every four weeks until complete response or disease worsening/progressing.

Detailed Description: This is a multicentre clinical study conducted in the United Kingdom. It is an open label study designed to investigate objective response rate (RR), the time to progression (TTP) and the duration of tumor response in patients with colorectal cancer when treated with CP-4055. The quantitative and qualitative toxicities of the treatment will also be assessed.